Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

被引：0
|
作者：
Ghanem, Hady [1 ]
Kantarjian, Hagop M. [1 ]
Ravandi, Farhad [1 ]
Cortes, Jorge E. [1 ]
Pemmaraju, Naveen [1 ]
Faderl, Stefan [1 ]
Dellasala, Sara E. [1 ]
O'Brien, Susan M. [1 ]
Burger, Jan A. [1 ]
Borthakur, Gautam [1 ]
Kadia, Tapan M. [1 ]
Quintas-Cardama, Alfonso [1 ]
Brandt, Mark [1 ]
Pierce, Sherry A. [1 ]
Garcia-Manero, Guillermo [1 ]
Jabbour, Elias J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4939.4939
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4939
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Ravandi, Farhad
    Plunkett, William
    Gandhi, Varsha
    Faderl, Stefan
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Brandt, Mark
    Huang, Xuelin
    Jabbour, Elias
    [J]. BLOOD, 2011, 118 (21) : 1550 - 1550
  • [2] Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Cortes, Jorge
    Ravandi, Farhad
    Plunkett, William
    Gandhi, Varsha
    Faderl, Stefan
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan
    Konopleva, Marina
    Brandt, Mark
    Huang, Xuelin
    Kantarjian, Hagop
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (04): : 244 - 251
  • [3] A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Ghanem, Hady Antoine
    Ravandi, Farhad
    Faderl, Stefan
    Cortes, Jorge
    Reyes, Ardes S.
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Kantarjian, Hagop M.
    [J]. BLOOD, 2010, 116 (21) : 903 - 903
  • [4] A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Ghanem, H.
    Kantarjian, H.
    Garcia-Manero, G.
    Ravandi, F.
    Faderl, S.
    Cortes, J. E.
    Reyes, A.
    O'Brien, S. M.
    Borthakur, G.
    Kadia, T. M.
    Burger, J. A.
    Konopleva, M.
    Jabbour, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    [J]. BLOOD, 1999, 94 (10) : 234B - 234B
  • [6] Phase I study of clofarabine plus Idarubicin and Clofarabine plus Idarubicin plus Cytarabine (ARA-C) in patients (PTS) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML).
    Faderl, S
    Ferrajolil, A
    Wierda, W
    Verstovsek, S
    Ravandi-Kashani, F
    Garcia-Manero, G
    Estey, E
    Thomas, DA
    Kornblau, S
    Kwari, M
    Gandhi, V
    Kantarjian, HM
    [J]. BLOOD, 2004, 104 (11) : 501A - 501A
  • [7] Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Assi, Rita
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Kadia, Tapan
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Jain, Nitin
    Daver, Naval
    Uehara, Taisuke
    Owa, Takashi
    Borthakur, Gautam
    [J]. BLOOD, 2017, 130
  • [8] A phase I/II study of induction therapy with topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Godwin, J
    White, C
    Beltran, O
    Stiff, P
    [J]. BLOOD, 2000, 96 (11) : 214B - 214B
  • [9] Troxatyl™ plus topotecan, ara-C, or idarubicin in patients (pts) with refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or blastic-phase chronic myeloid leukemia (CML-BP):: A randomized Phase I/II study.
    Giles, FJ
    Faderl, S
    Thomas, DA
    Cortes, J
    Jeha, SS
    Garcia-Manero, G
    Douer, D
    Levine, AM
    Estey, EH
    Beran, M
    O'Brien, S
    Koller, C
    Andreeff, M
    Kantarjian, H
    [J]. BLOOD, 2001, 98 (11) : 594A - 594A
  • [10] Phase II trial of arsenic trioxide (AS203) in patients (PTS) with relapsed/refractory acute myeloid leukemia (AML), blast crisis of CML, or myelodysplasia (MDS).
    Wiernik, PH
    Dutcher, JP
    Gallagher, R
    Caliendo, G
    Garl, S
    Paietta, E
    [J]. BLOOD, 1999, 94 (10) : 510A - 510A
12345